1. Ponatinib Inducing a Panuveitis with Choroidal Effusions and Neurosensory Retinal Detachment in a Patient with Chronic Myeloid Leukaemia
- Author
-
A D Patil, D McGonagle, O C Backhouse, and K Bhan
- Subjects
Male ,medicine.drug_class ,Chronic myeloid leukaemia ,Tyrosine-kinase inhibitor ,Choroidal effusion ,Uveitis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,hemic and lymphatic diseases ,Panuveitis ,medicine ,Humans ,Immunology and Allergy ,Protein Kinase Inhibitors ,030203 arthritis & rheumatology ,business.industry ,Ponatinib ,Imidazoles ,Retinal Detachment ,Myeloid leukemia ,Retinal detachment ,medicine.disease ,Pyridazines ,Ophthalmology ,chemistry ,Male patient ,030221 ophthalmology & optometry ,Cancer research ,Uveomeningoencephalitic Syndrome ,business ,Choroidal Effusions - Abstract
We present the case of a 50 year old male patient being treated for chronic myeloid leukemia by the tyrosine kinase inhibitor, Ponatinib. After 3 months of treatment, he developed a sight-threatening granulomatous panuveitis in both eyes, with choroidal effusions and neurosensory retinal detachments. Except for a positive interferon-gamma release assay suggesting previous Tuberculosis exposure, all uveitis investigations were normal. Discontinuation of the suspected causative drug led to resolution of signs and a consequent improvement in visual acuity.Ponatinib use may be associated with with a uveitic phenotype that is reminiscent of Harada's disease. We compare and contrast this rare ocular phenomenon with Vogt-Koyanagi-Harada syndrome and discuss a possible immunological basis.
- Published
- 2021
- Full Text
- View/download PDF